Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

by Li Li, Lan Deng, Xiaoqing Meng, Changling Gu, Li Meng, Kai Li, Xuesai Zhang, Yun Meng, Wei Xu, Le Zhao, Jianhe Chen, Zhenping Zhu, Haomin Huang
Published 2021-01-01